DDIT3 and diffuse large B-cell lymphoma: Additionally, 10–25% of tumors from newly-diagnosed GCB DLBCL/HGBL patients demonstrate poor-risk gene expression profiles which assign them to a subgroup (double hit signature, molecular high grade) which is also associated with inferior survival following receipt of first line R-CHOP [4, 5].